CryoPort, Inc. $CYRX Shares Purchased by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its holdings in CryoPort, Inc. (NASDAQ:CYRX) by 57.7%, now owning 377,127 shares valued at approximately $2.29 million.
• Wall Street analysts are optimistic about CryoPort, with a consensus rating of "Buy" and a target price of $12.00, following multiple upgrades and positive research reports.
• CryoPort reported earnings with a loss per share of ($0.29), missing expectations, but surpassed revenue estimates with $45.45 million for the quarter.

Trexquant Investment LP boosted its holdings in CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 57.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 377,127 shares of the company's stock after acquiring an additional 137,989 shares during the quarter. Trexquant Investment LP owned 0.75% of CryoPort worth $2,293,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Ieq Capital LLC acquired a new stake in CryoPort in the 1st quarter valued at approximately $206,000. MetLife Investment Management LLC increased its position in CryoPort by 13.8% in the 1st quarter. MetLife Investment Management LLC now owns 24,641 shares of the company's stock valued at $150,000 after acquiring an additional 2,980 shares during the period. Walleye Capital LLC increased its position in CryoPort by 21.7% in the 1st quarter. Walleye Capital LLC now owns 38,021 shares of the company's stock valued at $231,000 after acquiring an additional 6,776 shares during the period. Hsbc Holdings PLC increased its position in CryoPort by 96.7% in the 1st quarter. Hsbc Holdings PLC now owns 62,405 shares of the company's stock valued at $419,000 after acquiring an additional 30,671 shares during the period. Finally, Versor Investments LP acquired a new stake in CryoPort in the 1st quarter valued at approximately $177,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CYRX has been the topic of several research analyst reports. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price target on the stock in a research report on Wednesday, August 6th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price target on shares of CryoPort in a research report on Thursday, May 8th. Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. BTIG Research lowered their price target on CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. Finally, Stephens initiated coverage on CryoPort in a research report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $12.00.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $8.50 on Thursday. The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $425.60 million, a price-to-earnings ratio of 6.39 and a beta of 1.62. The stock's fifty day simple moving average is $7.94 and its 200 day simple moving average is $6.75. CryoPort, Inc. has a 52-week low of $4.58 and a 52-week high of $9.48.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The company had revenue of $45.45 million during the quarter, compared to analyst estimates of $41.74 million. CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%. CryoPort has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Robert Stefanovich sold 9,300 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total value of $80,631.00. Following the completion of the sale, the chief financial officer owned 207,213 shares of the company's stock, valued at $1,796,536.71. This trade represents a 4.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Edward J. Zecchini sold 51,500 shares of the firm's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total value of $352,260.00. Following the completion of the sale, the insider directly owned 90,411 shares of the company's stock, valued at approximately $618,411.24. This trade represents a 36.29% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 492,247 shares of company stock valued at $3,384,579. Insiders own 10.10% of the company's stock.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort, Inc. (NASDAQ:CYRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.